Explore every episode of the podcast OIS Podcast | Ophthalmology's leading Podcast

Adrienne Graves, Ph.D. returns, this time on The Rob & Jai Show, an edition of the OIS podcast. As a trailblazer of the industry, Dr. Graves shares her insights and lessons learned as a CEO and board member of several companies. She also discusses getting treatment to areas around the world that need it the most, how AI will affect and continue to impact eyecare and healthcare at large, and utilizing ophthalmic data for systemic disease diagnosis and management. 

In this episode of the OIS podcast, learn about:  

• Getting affordable and accessible ophthalmological therapies across the world 
• The differences between being a CEO and a board member 
• The impact of AI on eyecare and how it applies to practices 
• The next hot topic of ophthalmology 

RESOURCES:  

Dr. Rob Rothman: https://ois.net/robert-rothman-md/ 
Dr. Jai Parekh: https://ois.net/jai-g-parekh-md-mba/  

Adrienne Graves, Ph.D.: https://www.linkedin.com/in/adriennegraves  

Theresa Heah, M.D., MBA, co-founder, vice-chair, and CEO of Eyexora, speaks with host Carey Powers at this year’s Ophthalmology Innovation Summit about her company’s fresh approach to building an ophthalmology company that centralizes R&D, clinical, regulatory, and commercial expertise into a “one-stop shop.” Heah delves into the advantages of the hub and spoke model and how it will help overcome the gaps in the eye care landscape, as well as their plans to expand to the UK. 

In this episode of the OIS podcast, learn about:  

· Eyexora’s mission as a unique hub and spoke company dedicated to accelerating clinical innovation 

·  The barriers in the ophthalmology field and how Eyexora’s approach will help overcome them 

·  The advantages of building relationships on a global scale 

·  Milestones and scientific areas to look out for in 2026 

RESOURCES:  

Carey Powers: https://ois.net/carey-powers/  

Theresa Heah: https://www.linkedin.com/in/theresaheah  

Eyexora: https://eyexora.com/ 

Grace Ambrose-Zaken, Ph.D., president and CEO of Safe Toddles, speaks with host Robert Rothman about her mission to create a safer, easier-to-navigate world for children—perhaps one of the most underserved patients in eye care. Dr. Ambrose-Zaken discusses her breakthrough invention, the Pediatric Belt Cane, and how it transformed early mobility for blind children. 

In this episode of the OIS podcast, learn about:  

• Why we need to have empathy and understanding for the visually impaired, especially children 
• The advantages of the belt cane over the white cane 
• The impediments of getting the belt cane to patients 
• How to support the visually impaired and Safe Toddles’ mission 

What are the key qualities to being effective teammates? David Esposito, President and CEO of ONL Therapeutics, and Connie Chang, Chief Operating Officer of ONL Therapeutics, chat with host James Murray on the importance and value of transparency, trustworthiness, vulnerability, and candor amongst leadership to establish a strong company foundation.
In this episode of the OIS podcast, learn about:

• Handling the little problems before they become big problems
• The ability to execute big ideas effectively and efficiently
• Building trust between companies, investors, and all other parties
• Navigating the challenges of scaling

At this year’s Retina Innovation Summit, industry experts and leaders gathered in a two-part discussion on investment trends, regulatory environment and FDA changes, emerging therapies in ophthalmology, and more. Panelists include: Laura Feinleib, Managing Director at Redmile Group; Derrick Li, Chief Strategy Officer at ODC Life Sciences; Cameron Taylor, Managing Director at BofA Securities | Life Sciences; Wayne Caulder, Vice President & General Manager of Surgical (U.S. & Canada) at Bausch + Lomb; Paul Hallen, Vice President & Distinguished Fellow at Alcon; Nida Sen, MD, VP, Ophthalmology Strategy & Development Head at Sanofi; and Julian Smith, General Manager Portfolio Commercial Strategy - Eye Care at AbbVie.

In this panel learn about:
🔹Investment trends in public and private markets
🔹Regenerative therapies, such as gene therapy and cell therapy
🔹The impact of patient and therapy adoption challenges—and how to navigate them
🔹Advice for entrepreneurs and start-ups on the best key strategies on driving partnership interest and networking

Join Dr. Robert Rothman as he talks with Rajan Shukla about his journey from a family legacy in ophthalmology to pioneering new treatments for anterior segment diseases. Rajan shares how Vital Tears is making serum tears accessible nationwide and how Bright Star Therapeutics is developing innovative therapies like BrightMEM™ to transform ocular surface care.
In this episode, learn about:

• The story behind Vital Tears and Bright Star Therapeutics
• BrightMEM™ and its impact on treating limbal stem cell deficiency
• The future of ocular surface and retinal therapies

Hear how innovation is shaping the future of eye care.

This week on The Rob & Jai Show, an edition of the OIS Podcast, Dr. Rob Rothman and Dr. Jai Parekh welcome Tomas Navratil, PhD, Chief Development Officer at Glaukos, to discuss the company’s remarkable transformation from MIGS pioneer to a diversified global leader in ophthalmology. Glaukos is advancing a robust pipeline that spans devices, pharmaceuticals, and drug-device combinations—reshaping the future of eye care.

Highlights from the episode include:

• How Glaukos tripled its R&D pipeline over the past decade
• A shift from 100% device focus to 70% pharma or drug-device innovation
• Next-gen iDose TR with double the payload heading into clinical development
• Positive Phase 3 results for Epioxa, a non-surgical therapy for keratoconus

Tune in now to hear how Glaukos is stepping into its next chapter as a true ophthalmic powerhouse.

This week on The Rob & Jai Show, an edition of the OIS Podcast, Rob Rothman and Jai Parekh welcome Shawn O'Neil, President and Chief Commercial Officer of ViaLase, to discuss a cutting-edge advancement in glaucoma treatment. Velas is pioneering the FLIGHT procedure—Femtosecond Laser Image-Guided High-Precision Trabeculotomy—a non-invasive, incision-free alternative to traditional surgery. Highlights from the episode include:

• How ViaLase combines femtosecond laser precision with advanced OCT imaging
• The benefits of a non-surgical, office-based glaucoma treatment
• ViaLase’s newly secured CPT code (0730T) and reimbursement strategy
• Regulatory milestones, including CE Mark approval and upcoming U.S. trials
• The long-term potential of FLIGHT to serve patients across the glaucoma journey

Tune in to learn how this technology could redefine glaucoma care for both physicians and patients.

This week on The Rob & Jai Show, an edition of the OIS Podcast, Perry Sternberg, CEO of Sydnexis, discusses the company's efforts to bring its innovative SYD-101 product to market, which aims to slow the progression of pediatric myopia.

• Challenges in Market Access: Sternberg emphasizes the challenges of market access and reimbursement, explaining that it's not just about the product’s price but also the value proposition it offers.
• Launch Plans for 2026: The company is planning for a 2026 launch, following FDA approval, with a strong focus on ensuring a positive experience for both physicians and patients.
• Global Significance of SYD-101: He highlights the global significance of SYD-101, particularly in regions with high rates of myopia like Asia, where the need for effective solutions is critical.
• Personal Mission: Reflecting on his personal mission, Sternberg expresses his desire to make a meaningful impact on children’s vision and future health.
  The hosts applaud his leadership and the potential of this product to make a lasting difference in the lives of patients affected by progressive myopia.
  
  To learn more about SYD-101 and the exciting developments in pediatric myopia treatment, be sure to listen to the full podcast episode!

In this edition of The Rob & Jai Show, the OIS Podcast welcomes Adam Szaronos, CEO of IanTrek, for a wide-ranging conversation on innovation, leadership, and unlocking new pathways in glaucoma care. Adam walks us through his career journey from Alcon to TearLab to leading IanTrek, where he’s now championing a new class of glaucoma procedures with AloeFlow™—a minimally invasive, tissue-based implant that activates the uveoscleral pathway.

Together with hosts Dr. Rob Rothman and Dr. Jai Parekh, Adam discusses:

• The evolution of his career from medical device sales to surgical commercialization and C-suite leadership.
• Why the uveoscleral pathway, long leveraged in pharmacology, has remained unaddressed in surgical glaucoma—and how IanTrek is changing that.
• The material science breakthrough that differentiates AloeFlow™ from past uveoscleral attempts like CyPass.
• The market opportunity for post-MiGs patients and how IanTrek’s platform opens new treatment options without burning surgical real estate.
• Insights into IanTrek’s growing bio-interventional pipeline and what’s ahead in 2025 and beyond.

Whether you’re a glaucoma surgeon, an investor, or a medtech strategist, this episode is a must-listen on where glaucoma innovation is headed.

Subscribe to the OIS Podcast today and stay connected to the future of ophthalmology.

In this edition of The Rob & Jai Show, Paul Smith, President & COO of Orasis Pharmaceuticals, joins Dr. Rob Rothman and Dr. Jai Parekh for a compelling conversation on his career path and the commercialization of Qlosi™—a novel, FDA-approved, low-dose pilocarpine eye drop for the treatment of presbyopia.

With more than two decades of experience across Alcon, Novartis, and now Orasis, Smith reflects on his unique career trajectory from tech startups to ophthalmic leadership, the importance of cross-functional experience, and how a shared vision with founder & CEO Elad Kedar led him to the helm of a company now reshaping the presbyopia landscape.

In this episode, you'll learn:

• Why Qlosi™ was formulated at the lowest approved concentration of pilocarpine to prioritize safety, tolerability, and functional vision.
• How Orasis is differentiating its launch by learning from past category efforts and focusing on real-world expectations and patient needs.
• The company’s go-to-market strategy, including a hybrid access model and the role of optometry in driving adoption.
• Why Paul believes innovation in eye care thrives on collaboration, humility, and continuous learning.
• What makes presbyopia such a powerful entry point into the broader continuum of vision care.

With a clear mission, strong leadership, and a product designed with patients in mind, Orasis is setting a new standard in treating one of the most common unmet needs in eye care.

Don’t miss this thoughtful and inspiring discussion—subscribe to the OIS Podcast today to stay ahead of what’s next in ophthalmic innovation!

In this edition of the OIS Podcast, a powerhouse panel of investment, banking, and biotech leaders offers unfiltered insights on the current and future state of the ophthalmic industry. Featuring Andrew Gitkin (Leerink Partners), Cameron Taylor (Bank of America), Susan Orr, PhD (Claris Bio), and Anupam Dalal, MD (Acuta Capital), and Dr. Pravin Dugel, Chairman and CEO of Ocular Therapeutix, this session explores how macroeconomic and political shifts—such as RFK Jr.'s FDA rhetoric and rising interest rates—are influencing capital markets, regulatory confidence, and biotech strategy.
 
With humor, candor, and deep expertise, the panel discusses:
 
🔹The real impact of market volatility and regulatory speculation on investment in early-stage biotech.
🔹Why high-quality innovation still commands attention, even in uncertain times.
🔹How strategic interest in ophthalmology is evolving, and why later-stage assets may be getting more attention.
🔹Why board functionality may be the most underappreciated variable in getting a deal done.
🔹Trends in wet AMD, GA, and the wide-open opportunities in dry AMD and geographic atrophy.

If you’re a startup navigating today’s market, an investor looking for the next big breakthrough, or a strategist planning your pipeline, this is one episode you can’t afford to miss.
 
Don’t miss this compelling conversation. Subscribe to the OIS Podcast today and stay connected to the future of ophthalmology.

In this episode of The Rob & Jai Show, Michael O’Rourke, CEO of Re-Vana Therapeutics, joins Dr. Rob Rothman and Dr. Jai Parekh to explore the next-generation of sustained drug delivery in ophthalmology. With millions of intravitreal injections administered annually for retinal diseases like AMD, the need for longer-lasting, more effective treatments has never been greater.

O’Rourke explains how Re-Vana’s proprietary hydrogel-based technologies are setting a new standard for biodegradable, sustained-release drug implants—offering six to twelve months of therapeutic coverage without the need for surgery. The discussion covers:

🔹How Re-Vana’s EyeLief™ and OcuLief™ technologies work to deliver biologics efficiently over extended periods.
🔹Why reducing injection frequency is critical for patient compliance, physician workflow, and overall treatment success.
🔹 The company’s clinical and investment strategy, including a $70M Series B raise to advance its lead asset, a six-month biodegradable fluocinolone acetonide implant.
🔹 The role of strategic partnerships in accelerating innovation, as major pharma companies seek delivery solutions for their retinal therapeutics.
🔹 The global impact of sustained-release biologics, and how Re-Vana is positioning itself as a leader in both the U.S. and European markets.

With a team of seasoned industry experts, strong investor backing, and an unwavering commitment to innovation, Re-Vana Therapeutics is redefining how we approach retinal disease treatment.

Don’t miss this insightful conversation—subscribe to the OIS podcast today and stay ahead of the curve in ophthalmic innovation!

In this episode of The Rob & Jai Show, Dr. Rob Rothman and Dr. Jai Parekh host a captivating conversation with Andrew Stewart and Anthony Wallace—two leaders who are among the most experienced and admired executives in ophthalmology. Andrew Stewart, with over 25 years of pharmaceutical leadership across Bausch + Lomb, AbbVie, and Allergan, shares how his global business acumen shapes innovation in eye care. Anthony Wallace, a 26-year healthcare veteran with leadership roles at Novartis, Merck, and GlaxoSmithKline, reflects on leading Bausch + Lomb’s U.S. Surgical business and his passion for patient-centered solutions. Both leaders bring a wealth of knowledge, relatable stories, and a shared commitment to advancing ophthalmic care.

In this episode, you’ll learn:
🔹How Andrew Stewart and Anthony Wallace’s extensive pharmaceutical backgrounds influence their leadership in ophthalmology.
🔹Key trends shaping the future of pharmaceutical and surgical innovations in eye care.
🔹Insights into fostering strong organizational cultures that prioritize patient outcomes.
🔹Strategies for navigating the complexities of global ophthalmology markets.
🔹Personal reflections on leadership, mentorship, and maintaining passion for patient impact.

Don't miss this inspiring conversation with two leaders whose expertise, warmth, and dedication continue to shape the future of ophthalmology. Subscribe to the OIS podcast today and stay ahead of the curve in eye care innovation!

In this OIS Podcast episode, host Dr. Robert Rothman sits down with Daphne Haim-Langford, PhD, Founder & CEO of Tarsier Pharma, and Ashley Kline, Chief Commercial Officer, to discuss their groundbreaking approach to uveitis treatment.

Tarsier’s lead candidate, TRS01, is a first-in-class bio-inspired therapy designed to control inflammation without raising intraocular pressure, a major complication of steroid treatments. With a unique mechanism of action that modulates macrophages and reduces inflammation, this novel drug has the potential to redefine uveitis and glaucoma care.

In this episode, you’ll learn:

🔹 How Tarsier’s bio-inspired molecule is changing the game in ophthalmology.

🔹 Why steroids, despite being the standard of care, can be problematic for uveitis patients.

🔹 The challenges of scaling manufacturing and securing regulatory approval for novel ophthalmic treatments.

🔹 Insights from Ashley Kline on the commercial strategy for launching Tarsier’s therapy.

🔹 How Dr. Rothman sees this innovation reshaping ophthalmology and glaucoma treatment.

🎧 Tune in to hear how Tarsier Pharma is working to bring a safer, more effective treatment to market! Subscribe to the OIS Podcast today!

In this episode of Eye on Innovation, host Carey Powers introduces the Next-Gen Innovators series with special guest Dr. Vikram Shankar, an ophthalmologist at Stanford and co-founder of Dropmate. Dr. Shankar discusses how his passion for public health and patient care inspired the creation of Dropmate—a compact, affordable, and eco-friendly disinfection system for clinical eye care equipment. Learn how this technology addresses patient safety, cost savings, and environmental sustainability, all while transforming the standard of care in ophthalmology.

In this episode, you’ll learn:

• How Dropmate revolutionizes the disinfection process for eyedropper bottles, tonometer tips, and other eye care devices.
• The significant cost savings and sustainability impact of Dropmate on clinics and ASCs.
• Dr. Shankar’s inspiring journey from public health to ophthalmology and innovation.
• Insights into building a successful medical startup, including mentorship, partnerships, and overcoming challenges.
• The milestones Dropmate has achieved in 2024 and its ambitious goals for 2025.

Discover how Dr. Vikram Shankar is shaping the future of eye care with innovation and sustainability at the forefront. Subscribe to the Eye on Innovation Podcast today and stay ahead of the curve!

In this episode of The Rob and Jai Show, Dave LeCause, a renowned biopharmaceutical leader and former VP of Allergan Eye Care, reflects on his remarkable career in ophthalmology. Join us as Dave discusses his journey from leading commercial strategies for billion-dollar brands to mentoring the next generation of innovators. Hear his thoughts on innovation cycles, the evolving landscape of dry eye treatments, and why gene and cell therapies hold the key to ophthalmology’s future.

In this episode, you’ll learn:

• How Dave LeCause helped shape the commercial success of leading ophthalmic brands.
• His perspective on dry eye innovation and the market’s ongoing growth potential.
• Why gene and cell therapy excite him as the next frontier in eye care.
• Insights into the evolving role of strategic partnerships and commercialization strategies in startups.
• The unique opportunities and challenges facing the eye care sector today.

Don’t miss this inspiring conversation with one of ophthalmology’s most influential leaders. Subscribe to the OIS podcast today!

In this double-feature episode of the OIS Eye on Innovation Podcast, Carey Powers highlights the invaluable resources and expertise within the OIS community, showcasing the power of cross-collaboration and strategic foresight in biotech.

Part 1:
Dr. Francis Lasowski (C20/20 Innovation Hub) and Dr. Wendy Naimark (Ripple Therapeutics) discuss their long-standing partnership, which has propelled Ripple's success through groundbreaking innovations, including dry AMD research and key advancements in IP management. Learn how the Innovation Hub provides early-stage companies with critical resources to navigate the challenges of development and commercialization.

Part 2:
Tracy Valorie, a biotech and pharma veteran, explains why early commercial strategy is the key to success. From understanding market access and reimbursement to planning for manufacturing readiness, Tracy shares actionable tips for startups to avoid costly mistakes and maintain a commercial mindset throughout product development.

In this episode, you’ll learn:

• How partnerships, like C20/20 and Ripple Therapeutics, foster early-stage breakthroughs.
• The role of innovation hubs in overcoming funding and IP challenges.
• Why a commercial strategy must start at the angel investing stage.
• How to integrate market research and manufacturing readiness into development plans.
• The power of collaboration and strategic foresight to accelerate biotech success.

Discover how cross-industry partnerships and early commercial planning can bridge the "valley of death" in biotech. Tune in to this episode and leverage the collective wisdom of the OIS community!

In this episode of The Rob and Jai Show from OIS XIV, hosts Dr. Rob Rothman and Dr. Jai Parekh talk with Eric Schlumpf, CEO of Stuart Therapeutics, about the company’s transformative approach to ophthalmic diseases. Learn how Stuart's innovative polypeptide technology repairs damaged collagen, advancing from dry eye to neuroprotection in glaucoma and beyond. Eric highlights key milestones, including promising clinical trial results, strategic partnerships, and the company’s plans to tackle major unmet needs like myopia and inherited retinal diseases.

In this episode, you’ll learn:

• How Stuart Therapeutics’ polypeptide platform is revolutionizing ophthalmic treatments.
• The potential for neuroprotection in glaucoma and what makes Stuart’s approach unique.
• Why Stuart’s dry eye clinical program could be a market differentiator.
• The exciting data supporting new indications like myopia and inherited retinal disease.
• How strategic partnerships are fueling innovation in a capital-efficient way.

Tune in for an engaging conversation on the cutting edge of ophthalmic innovation, and find out why Stuart Therapeutics is one of the hottest companies to watch in ophthalmology.

Carey Powers caught up with five innovative companies at this years OIS XIV in San Diego, to discuss the latest advancements in ophthalmology on the OIS podcast.

Topics included touchless laser therapy for presbyopia, extending the duration of intravitreal treatments, next-generation tear fluid testing, and new imaging methodologies for vitreoretinal conditions. Guests include:

• Alex Lopez, Chief Commercial Officer - Ace Vision Group
• Houman Hemmati, MD, PhD, Co-Founder & Chief Medical Officer - Optigo Biotherapeutics
• Leanne Lavriola, DO, MBA, President & CEO - InnSight Technology
• Nir Katchinskiy, PhD, CEO & Co-Founder - PulseMedica

In this episode, listen in as Dr. Robert Rothman speaks with Dr. Daniel Brocks, CMO of BostonSight! They discuss the unique PROSE lenses that are redefining corneal care and how BostonSight’s nonprofit mission is making advanced treatments accessible to more patients. Key takeaways include:

• PROSE Lenses: Customized scleral lenses that protect, hydrate, and restore vision for complex eye conditions.
• Increased Accessibility: BostonSight’s new tech-driven approach to simplify lens fitting for broader use.
• Mission-Driven Impact: How BostonSight reinvests revenue to offer free care and support for patients in need.

Join us to learn more about these innovations and the future of specialty eye care—tune in now!

In this episode of the OIS Retina Podcast, Firas Rahhal sits down with Jean-Pierre Hubschman, CEO of Horizon Surgical, to discuss the revolutionary advancements in robotic eye surgery. Highlights include:

• The development of the "IRISS" robotic platform and its focus on cataract surgery.
• Insights into AI-driven precision, decision-making, and visualization in surgery.
• Challenges of transitioning from academia to a successful medtech startup.
• Future potential for robotics in glaucoma, retina, and other ophthalmic procedures.

Listen now to hear how AI and robotics are transforming eye surgery!

In this episode of the OIS Podcast, host Rob Rothman sits down with Jay Cormier, CEO of Eyedaptic, to explore innovative solutions for individuals with vision loss. They discuss Eyedaptic's groundbreaking technology and its impact on enhancing daily life for those with visual impairments.

Key Highlights:

• Insight into the inspiration behind Eyedaptic and its mission to improve independence for the visually impaired.
• Overview of the EYE5 product, an augmented reality solution that enhances mobility and connection to the environment.
• Discussion on the recent launch of Ivy, an AI visual assistant that transforms user interaction with their surroundings.
• Importance of targeted marketing and in-person demos for increasing accessibility to Eyedaptic’s products.

Join us to discover how Eyedaptic is revolutionizing the way we think about vision care!

In this week’s OIS Podcast episode, Host Dr. Robert Rothman sits down with Almog Aley-Raz, CEO of CorNeat Vision, for a fascinating discussion. They cover:

• Almog’s career journey from Israel to the U.S.
• How a mountain biking trip with an ophthalmologist sparked the idea for CorNeat Vision
• Corneal blindness as a global issue and the need for better solutions, especially in regions with limited donor tissue and trained surgeons
• CorNeat's groundbreaking synthetic cornea, made with their unique material, Avatrix, which offers exciting potential for restoring vision
• Applications of Avatrix beyond ophthalmology, including maxillofacial and dental procedures

Tune in now to learn more!

Exciting insights from the OIS Retina Panel! Moderated by Dr. Emmett Cunningham, this discussion dives deep into the current state of ophthalmology investment and innovation. Panelists, Anna Chen, Adit Ghosh, Dr. Firas Rahhal and Caroline Stout shared their perspectives on the evolving landscape, highlighting both opportunities and challenges in the field.

Here are the key takeaways:

• Cautious Optimism: A resurgence in private markets, but drug development challenges persist.
• Growth Areas: Focus on drug delivery, extended-release biologics, and complement inhibitors for dry AMD/GA.
• Strategic Partnerships: Crucial for commercialization in ophthalmology.
• Emerging Trends: AI’s potential impact and regulatory changes in drug discovery.
• Market Concerns: Uncertainties around gene therapy and commercial viability.

Don’t miss out—listen in now to gain valuable insights!

Don’t miss the OIS Retina Panel, moderated by Dr. Pravin Dugel, “The View from the Street.” Join Dr. Anupam Dalal, Andrew Gitkin, and Cameron Taylor as they discuss the latest in ophthalmology, including:

• Current Challenges: Few blockbuster drugs and limited M&A activity
• Opportunities: Growth potential from recent GA therapy successes
• Strategic Insights: Importance of community and networking

Get valuable insights from industry experts and stay ahead of the curve. Listen in now!

Discover the milestone 400th episode of the OIS podcast with Dr. Firas Rahhal and Dr. Robert Rothman, where they explore the impact of Ophthalmology Innovation Summit (OIS) on the investment ecosystem:

• Journey of OIS
• Rich Insights
• Collaboration
• Clinical Mastery
• Long-Term Relationships
• Humor and Admiration
• Future of Ophthalmology

Tune in to this episode for a blend of knowledge, inspiration, and laughter as they navigate the future of eye care innovation. Don’t miss out—listen now!

In this episode of Eye on Innovation Podcast, Carey Powers delves into the latest advancements in corneal crosslinking technology with expert guest Dr. Deepinder Dhaliwal. Dr. Dhaliwal, a renowned professor of ophthalmology at the University of Pittsburgh School of Medicine and director of refractive surgery at the UPMC Vision Institute, shares her extensive knowledge and insights. Here’s what you can expect:

• Prevalence of Keratoconus: Discover how improved diagnostic imaging has revealed a higher prevalence of keratoconus than previously thought, affecting 1.2% of 20-year-olds.
• Current Standard of Care: Learn about the FDA-approved epithelium-off crosslinking procedure and its role in treating progressive keratoconus in the U.S.
• Unmet Needs in Treatment: Understand the challenges of current crosslinking procedures, including patient discomfort, long recovery times, and the need for safer, faster options.
• Innovative Solutions: Get insights into upcoming advancements like epithelium-on crosslinking, which promises quicker recovery and fewer side effects.
• Future Directions: Hear about the potential for custom crosslinking procedures and the exciting work being done in the field to stabilize even very thin corneas.
• Early Detection: Explore the importance of early keratoconus detection through corneal tomography and the potential role of AI in identifying at-risk patients sooner.

Tune in to gain a comprehensive understanding of the latest innovations and future possibilities in corneal crosslinking technology. Don't miss this insightful conversation!

In our latest episode, host Dr. Rob Rothman interviews Greg Kunst, CEO of Aurion Biotech, to delve into the forefront of cell therapy for corneal disease. Join us to discover:

• Greg's journey from pivotal roles at Alcon and Glaukos to leading Aurion Biotech
• The innovative allogenic cell therapy technology developed by Aurion
• How this technology addresses the global shortage of corneal tissue
• Insights into the challenges and breakthroughs in scaling production and securing market approval
• Future applications of cell therapy in ophthalmology beyond corneal endothelial disease

Don't miss this fascinating conversation on the future of medical innovation in ophthalmology! Listen to the episode and subscribe to the OIS Podcast for more updates on the latest trends in eye care and medical technology.

This week's OIS Podcast features a compelling panel discussion from the Dry Horizons Symposium co-presented by Ora and OIS, held on May 3 in Seattle. The panel, comprising leading experts in ophthalmology and dry eye research, covered essential topics in the field:

🔹Advancements in Diagnostics: Insights into new tools and technologies for more accurate and reliable diagnosis of dry eye syndrome.
🔹Regulatory Challenges: Discussion on the regulatory landscape and the hurdles faced in gaining approval for innovative treatments.
🔹Artificial Intelligence in Dry Eye Management: Exploration of AI's potential to transform the management and treatment of dry eye through enhanced diagnostics and personalized care.
🔹The Quest for a Cure: Perspectives on the ongoing research efforts and the journey toward finding a cure for dry eye syndrome.

Tune in to hear the expert opinions and in-depth analysis shared by the panelists, providing a comprehensive overview of the current state and future directions of dry eye research and treatment.

Explore the cutting-edge world of ophthalmology with the Eye on Innovation Podcast. In the latest episode, Carey Powers hosts Dr. Rishi Singh and Dr. Michael Singer as they delve into how AI and robotics are transforming retina medicine, bringing unprecedented changes to diagnosis, clinical trials, and patient care. This insightful discussion provides valuable information for ophthalmologists, researchers, and anyone interested in the future of eye care. Here’s what you can expect from this episode:

• AI in Diagnostics: Learn how AI technology is streamlining and enhancing the accuracy of retina diagnostics through devices like Optical Coherence Tomography (OCT).
• Robotics in Surgery: Discover the challenges and opportunities of integrating robotics into retinal surgery, and what the future might hold for these advanced surgical techniques.
• Improved Clinical Trials: Find out how AI is enabling better patient selection and more efficient clinical trial processes, leading to potentially better outcomes.
• FDA Regulation: Understand the regulatory landscape and what it means for the adoption of AI and robotics in medical devices.

Don't miss this episode if you want to stay ahead in the rapidly evolving field of ophthalmology. Tune in now and be a part of the conversation shaping the future of eye care.

In this compelling OIS podcast episode, host Dr. Rob Rothman engages in an insightful conversation with Dr. Malvina Eydelman, the Director of the FDA's Office of Ophthalmic, Anesthesia, Respiratory, ENT, and Dental Devices. Delve into Malvina's unique career journey and discover how her diverse background in engineering and ophthalmology has influenced her work at the FDA.

 Here's what you can expect from this episode:

• Malvina's Journey: Learn how Malvina went from growing up in Georgia to becoming a key leader at the FDA, thanks to her strong engineering and medical background.
• FDA's Role in Innovation: Discover how the FDA is evolving to support innovation, with a focus on collaborative workshops and clear standards for ophthalmic devices.
• Leadership During COVID-19: Hear about Malvina's critical role during the COVID-19 pandemic, managing the rapid approval and production of ventilators and respiratory devices.
• Tips for Early Engagement with the FDA: Get valuable advice on how to navigate the FDA's processes and why early communication is crucial for success in medical device development.

This episode is a must-listen for anyone interested in the intersection of healthcare, technology, and regulatory processes. Click the link to listen now!

In the latest episode of the OIS podcast, host Dr. Rob Rothman delves into the transformative power of empathy with multi-Emmy award-winning actress and writer, Ellen Gould. Together, they explore the intersection of healthcare and storytelling, shedding light on the importance of patient-centered care and authentic narrative representation.

Episode Highlights:

• Personal Journey: Ellen shares her journey living with Stargardt's disease and its profound influence on her perspective and creative endeavors.
• Adversity to Opportunity: Discover how Ellen turned personal challenges into opportunities for artistic expression and meaningful storytelling.
• "Seeing Stars" Project: Get an inside look at Ellen's groundbreaking project, which amplifies the voices and experiences of individuals with visual disabilities.
• Authentic Storytelling: Rob and Ellen discuss the importance of authentic storytelling in portraying the real-life challenges and triumphs of people with disabilities.
• Future Outlook: Hear about Ellen's plans for the future and the ongoing impact of her work in promoting empathy and understanding.

Tune in to this inspiring episode as Rob and Ellen celebrate resilience, compassion, and the power of empathy in action. Join the conversation and let empathy guide your journey towards connection and understanding.

In this episode, Dr. Jai Parekh shares his journey from ophthalmology to business leadership in healthcare. Raised in New Jersey, he initially pursued cardiology before discovering his passion for ophthalmology. Specializing in cornea and refractive surgery, he transitioned into the commercial side of the field, leveraging his clinical expertise and business acumen.

Key points covered in the episode include:

• Transition into the commercial side of ophthalmology, leveraging clinical expertise and business acumen.
• Emphasis on the importance of physicians in shaping the healthcare industry and bridging the gap between clinical practice and business.
• Dedication to continuous learning, interdisciplinary collaboration, and innovation in advancing patient care and the field of ophthalmology.

Don't miss out on this exclusive opportunity to learn from a visionary leader in the field!

Don't miss the latest episode of the OIS Retina Podcast, where we sit down with optometrist and ophthalmology researcher Brian Levy for an illuminating discussion on the future of eye care. In this episode, Brian takes us on a journey through his career, from his early days in vet school to his groundbreaking work at Presbyterian Medical Center, Aerie Pharmaceuticals, Bausch + Lomb and currently at InflammX Therapeutics. Here are some key talking points from the episode:

🔹 Brian's transition from vet school to ophthalmology research.

🔹 His role in developing innovative ocular therapies.

🔹 Insights into the latest advancements in eye care technology.

🔹 Challenges and opportunities in the field of ophthalmology.

🔹 Future directions and trends shaping the landscape of eye care.

Tune in now to gain valuable insights and inspiration from one of the leading voices in the field!

Tune in to the latest episode of the Eye On Innovation podcast where Carey Powers dives into the dynamic world of biotech investor pitch decks with special guest Dr. Rob Rothman, Founding Partner of InFocus Capital Partners. Discover the top five mistakes to avoid when crafting your pitch deck and gain exclusive insights from Dr. Rothman's wealth of experience in ophthalmology and venture capital.

In this episode, you'll learn:

• The importance of tailoring your pitch deck to specific investors.
• Strategies for keeping your pitch deck concise and engaging.
• Why it's crucial to address challenges, competition, and reimbursement in your presentation.
• The art of storytelling and its impact on investor engagement.

Don't miss out on this enlightening discussion—subscribe to the OIS podcast today and stay ahead of the curve in biotech innovation!

Join us this week on the OIS podcast as host Carey Powers sits down with Dr. Paul Karpecki to explore the latest advancements in presbyopia treatment strategies. Here's what you can expect from this insightful conversation:

• Insider Insights: Dr. Karpecki shares insider insights gleaned from his extensive clinical experience and research in the field of presbyopia treatment.
• Financial Potential: Discover the potential for unprecedented financial gains in the rapidly evolving market of presbyopia treatment.
• Cutting-Edge Strategies: Uncover the latest cutting-edge strategies and developments in the treatment of presbyopia, offering hope and solutions to millions affected by this common eye condition.

Tune in to this episode for an in-depth look at the future of presbyopia treatment and the exciting opportunities it presents!

In the latest episode of the OIS Podcast, host Dr. Robert Rothman engages in a captivating dialogue with Dr. Prasad Sunkara, CEO of Eyegenex.

Key points discussed in the episode:

• Prasad's multifaceted background spanning agricultural sciences to pharmaceuticals.
• Eyegenex's pioneering work in gene and peptide therapies for ophthalmic conditions.
• The personal journey and insights driving Prasad's commitment to advancing ophthalmology.

For a deep dive into this thought-provoking conversation, tune in to the OIS Podcast and explore the forefront of ophthalmic innovation.

 This panel discussion on startup commercial strategy explores key elements and insights from industry leaders, Paul Bresge, Aziz Mottiwala, Todd Pinkney, Cari Stone and Adam Szaronos, offering a comprehensive view of the journey from regulatory approval to commercialization. Beth Marsh, Lead of Sales and Marketing at Apellis, sets the stage by emphasizing the importance of early consideration of commercial strategy.
 Key topics covered in the discussion include:

• Early Commercial Strategy
• Elements of Robust Strategy
• Raising Institutional Funding
• Evolution of Strategies
• Future Anticipation

Don't miss out – listen now for a comprehensive view of navigating the complexities of startup success!

OIS Podcast host Carey Powers speaks with Dr. Adrienne Graves and Dr. Barbara Wirostko on 'Maximizing the Value of Your Board of Director' live from OIS XIII.

Dr. Graves and Dr. Wirostko share valuable insights on:
* Building effective boards
* Significance of diversity
* CEO and board member communications
* Navigating decision-making
* Board dynamics
* Strategic collaboration

This episode is a must-listen for CEOs and founders navigating the intricacies of leadership and strategic decision-making. Tune in now.

In this episode of the OIS Podcast, host Dr. Firas Rahhal, along with expert panelists, Dr. Robert Bhisitkul, Dr. Alan Franklin and Dr. Paul Karpecki at OIS XIII, takes listeners on a deep dive into the transformative landscape of oral therapies in retina treatment, challenging the conventional approach dominated by eye injections. Tune in as they explore the groundbreaking realm of oral treatments and shed light on their novelty in retinal care.

The discussions are comprehensive, covering key aspects such as:

•  Novelty in Retina Treatment
•  Three-Step Improvement and Long-Term Vision Protection
•  Optimism for Prevention and Early Intervention
•  Clinical Trial Parameters and Market Potential
•  Diverse Mechanisms in Focus

Don't miss out on this enlightening episode that explores the dynamic landscape of oral therapies, offering a fresh perspective on their potential to revolutionize the field of ophthalmology. Stay informed and engaged with OIS XIII discussions, as experts discuss the exciting possibilities that oral therapies bring to the forefront of retinal treatment.

ViaLase, a clinical stage medical technology company located in Aliso Viejo, CA is focused on disrupting the conventional glaucoma treatment paradigm with the introduction of a truly noninvasive image-guided femtosecond laser treatment that enhances glaucoma patient care.

With a leadership team that has vast experience developing, designing, manufacturing, and commercializing the first femtosecond lasers for ophthalmic surgery for refractive and cataract patients, ViaLase is now bringing that expertise and innovation to glaucoma patients.

In this episode, Chief Commercialization Officer, Shawn O’Neil chats with OIS host Dr. Rob Rothman and discusses his successful product launches and instrumental contributions to ViaLase's commercialization strategy, their unique reimbursement strategy, the treatment's durability over time, enhancing its long-term impact, and much more.

Tune in and see how ViaLase plans to bring this revolutionary treatment to glaucoma patients across the globe.

Resources
ViaLase: https://www.vialase.com
Sean O’Neil: LinkedIn
Robert Rothman, MD ois.net/robert-rothman-md

Opthea, an Australian based biopharmaceutical company is dedicated to transforming retinal disease treatments and elevating patients' vision and quality of life. Join Firas Rahal, MD, in a captivating episode as he engages with Opthea's Founder and Chief Innovation Officer, Megan Baldwin, PhD.

Explore the compelling journey from oncology to ophthalmology, unraveling strategic decisions, navigating competitive landscapes, and achieving triumphs in clinical trials. Dr. Baldwin unfolds her remarkable career trajectory, from a PhD at the University of Melbourne to pivotal roles at Genentech and the Ludwig Institute for Cancer Research.

Tune in for exclusive insights, including:

• Opthea's strategic approach to revolutionizing eye care
• Clinical Trials: A deep dive into their success and impact
• Comparison with Other Drugs: Differentiating factors and unique contributions
• Future Directions: Exploring new horizons and clinical opportunities
• Commercialization Timeline: Anticipated milestones and FDA approval strategies

Listen now for a compelling journey through Opthea's vision as they continue to shape the landscape of ophthalmological advancements.

Opthea: Opthea.com
Megan Baldwin, PhD: LinkedIn
Firas Rahal, MD ois.net/robert-rothman-md

Harrow isn’t a household name (yet), but eye care professionals have trusted its products for over a decade.

The Nashville-based company produces Dexycu, an intraocular steroid; Iopidine for intraocular pressure control; and most recently, five Novartis products that Harrow acquired in December 2022.

Rob Rothman, MD, caught up with Harrow founder and CEO Mark Baum to find out how he grew the company from worse than nothing—he acquired, restructured, and reorganized a company in bankruptcy in 2011—to a publicly traded organization with an enterprise value of $750 million.

Baum describes Harrow as a “consortium of entrepreneurs.” That consortium includes:

• Eton Pharmaceuticals, developing products to treat rare disease
• Surface Ophthalmics, developing preservative-free products to treat dry eye disease and post-operative pain
• Melt Pharmaceuticals, which produces MKO Melt, an FDA-approved analgesic

Harrow built its business off compounded medications. By meeting needs of physicians in that way, it grew from zero to over 10,000 customers in a relatively short time.

Looking ahead, Baum wants to build Harrow’s portfolio and its brand recognition, all while abiding by the company’s mission: to give patients access to affordable ophthalmic medications.

Listen to the podcast today to discover:

• More about Baum’s career path, including his background as a lawyer and investor, his move into business, and the event that prompted him to reorganize and restructure what is now Harrow.
• Harrow’s corporate philosophy and why Baum considers the company a consortium of entrepreneurs.
• How Harrow grew from zero to over 10,000 customers in a few years.
• The secret to Harrow’s success, including how it profits from smaller, but no less important, assets.
• What’s next for Harrow, including the upcoming launch of Vevye, a dry eye drop based on Novaliq’s proprietary EyeSol water-free technology.
• How Harrow plans to grow within the next five years, and whether that includes developing its own products.

Resources

Harrow:                       harrow.com

Mark Baum:                marklbaum.com and on LinkedIn

Rob Rothman, MD      ois.net/robert-rothman-md

Endogena Therapeutics has developed a novel approach to regenerative medicine that’s not only scientifically compelling, but practical.

Endogena’s technology unlocks the body’s own stem cells for controlled tissue repair by small molecules. Its products use a dosing schedule that could move easily into the system already in place for intravitreal injections.

CEO Matthias Steger, PhD, MBA, sat down with retina specialist Firas Rahhal, MD, to discuss the Endogena approach in depth. They also discuss the compelling results seen so far in both animal models and in patients.

The company’s lead candidate is being developed to treat retinitis pigmentosa. The product has received Orphan Drug and Fast Track Designation from the FDA and is moving through Phase IIa clinical trials. Dr. Steger says the company expects to have data to share in early 2024. It’s also submitting an investigational new drug (IND) application for an age-related macular degeneration treatment later this month.

Listen to the podcast today to discover:

• The “serendipitous discoveries” that moved Dr. Steger’s career from applied science to financial analyst to regenerative medicine start-up cofounder.
• The stem cell approach that Dr. Steger and team are applying to Endogena products and how it differs from implanted stem cell programs.
• How Endogena applies its novel drug discovery approach to neurodegenerative retinal disease by rebuilding photoreceptors.
• The type and location of retinal stem cells used for Endogena treatments.
• The types of molecules used to stimulate or induce an effect from the stem cells.
• The incredible results the technology produced in mice—regenerating the outer retinal layer “nearly back to normal” and regenerating the rods and cones.
• The dosing schedule for the RP product and what happens after dosing is complete.
• How Endogena plans to fund its current and upcoming programs. Where has the funding come from to date? And for upcoming clinical trials?

Resources

Endogena Therapeutics          https://endogena.com

Firas Rahhal, MD                     https://ois.net/firas-m-rahhal-md

“You can see and feel a buzz within the company right now,” said Andrew Stewart, President, Global Pharmaceuticals and International Consumer, at Bausch + Lomb.

Bausch + Lomb’s current momentum stems not only from new leadership, but also from recent collaborations, partnerships, and acquisitions.

Stewart and Yehia Hashad, MD, Executive Vice President of Research & Development and Chief Medical Officer, join host Paul Karpecki, OD, to discuss these activities. Miebo, the first-in-class dry eye asset for the treatment of evaporative dry eye, tops the list.

Looking ahead, Stewart and Dr. Hashad said the company is lasering its focus to tackle more unmet medical needs in eye care. The company intends to build on its legacy of innovation in drug delivery, in MOAs, and in developing new molecular entities.

What’s next for the most recognized name in eye care?

Topics discussed include:

• Why Stewart shifted into commercial from R&D, and why Dr. Hashad moved from clinical practice to R&D.
• How Bausch + Lomb leadership is looking at the future for a company with a 170-year legacy.
• Bausch + Lomb’s holistic approach to dry eye disease and treatment.
• The company’s thinking behind acquiring the rights from Novaliq to pursue development of what is now Miebo.
• The importance of addressing unmet needs with respect to the Bausch pipeline.
• What excites Dr. Hashad and Stewart about the company right now.
• Where they would like to see Bausch + Lomb in the next three to five years, including for Miebo, for ocular surface disease treatments, and for eye care.

Resources

Miebo                         https://www.miebo.com

Andrew Stewart          https://www.bausch.com/about-bausch-lomb/leadership-team

Yehia Hashad, MD       https://www.bausch.com/about-bausch-lomb/leadership-team

Paul Karpecki, OD       https://ois.net/paul-karpecki-od

OIS Podcast host Carey Powers caught up with four ophthalmology execs and one principal investigator to talk about some of the most exciting developments in retina R&D.

Her guests include:

• Houman David Hemmati, MD, PhD, Cofounder and Chief Medical Officer of Optigo Biotherapeutics   
• Michael Tsipursky, MD, CEO and Cofounder of Revive Biotech
• Michael Singer, MD, Clinical Professor of Ophthalmology at University of Texas Health Science Center, Director of Clinical Research at Medical Center Ophthalmology Associates, and Principal Investigator for Unity Biotechnology’s BEHOLD trial
• Samarendra Mohanty, PhD, President and Cofounder; and Sulagna Bhattacharya, CEO and Cofounder of Nanoscope Therapeutics

Optigo is developing binders intended to extend the duration of top-performing intravitreal drugs without compromising efficacy. The company has already had promising results in clinical trials with aflibercept. What’s next?

Revive Biotech focuses on central retinal artery occlusion. Its products work by injecting oxygen-loaded nanobubbles into the eye intravitreally. Preclinical studies have advanced through proof of concept. Nanobubbles?

Dr. Singer is a principal investigator in Unity Biotechnology’s clinical trial for UBX-1325, a therapeutic in development to treat diabetic macular edema and wet AMD. If approved, the product could work as an adjunct to anti-VEGF therapies.

Nanoscope Therapeutics is developing gene therapies that focus on ambient light-sensitive molecules to treat inherited and acquired retinal diseases. Its lead product, MCO-010, is moving through Phase II trials. Why ambient light?

Tune in to hear today’s experts discuss:

• How Optigo plans to extend the duration of aflibercept
• The impact of extending duration activity on patients, physicians, and payers
• What Optigo plans to accomplish over the next 12 months
• What’s behind Revive Biotech’s proprietary technology and what makes it unique.
• The milestones it has completed so far with relation to clinical trials, intellectual property, and funding
• The new class of therapeutics being developed by Unity Biotechnology
• The data released so far on the UBX-1325 BEHOLD trial
• If approved, the impact of UBX-1325—an agent that may potentially extend the life of anti-VEGF therapies—on clinical practice
• The potential impact of Nanoscope Therapeutics’s MCO-010 on patient communities
• The feedback reported from clinical trial participants
• The critical milestones Nanoscope Therapeutics intends to achieve over the next year

[Listen Now]

OIS Podcast host Carey Powers speaks with four CEOs from leading retina-focus companies to talk about all things innovation. Her guests include:

•  Kerrie Brady, BPharm, President and CEO of OcuTerra
•  Rich Small, CEO of NeuroTech Pharmaceuticals
•  Kester Nahen, PhD, CEO of Notal Vision
•  Brad Doerschuk, President and CEO of InFocus Clinical

OcuTerra is developing OTT166, a novel small molecule designed to treat diabetic retinopathy.

The product is getting attention because it can deliver product to the retina via an eye drop application, said Kerrie Brady, BPharm, CEO of OcuTerra.

The company has completed enrollment for a Phase II trial in 225 patients with diabetic retinopathy. They hope to have topline results in early 2024.

Next up: Rich Small, CEO of NeuroTech Pharmaceuticals. The company’s Encapsulated Cell Therapy (ECT) technology enables continuous production of therapeutic proteins to the eye.

ECT is central to NT-501, a product being developed to treat macular telangiectasia (MacTel) as well as glaucoma.

Third in line: Kester Nahen, PhD, CEO of Notal Vision. Notal Vision provides remote patient monitoring services for patients with retinal diseases. Its teleconnected devices use AI and analytics to give physicians insight into retinal activity in between patient visits. The company is also developing a home OCT device that has received Breakthrough Device designation from the FDA.

Brad Doerschuk, CEO of InFocus Clinical, closes out the podcast by discussing the value of contracting with a specialist. He says InFocus is the first and only retina specialty CRO. The depth of ophthalmology expertise at the organization is hard to find, he says, and it enables the company to offer comprehensive, high-touch services to its clients.

Other topics covered on today’s episode include:

•  The mechanism of action of OcuTerra’s OTT166
•  The opportunities that arise from a noninvasive local therapy and how this type of therapy could transform the standard of care.
•  How NeuroTech’s ECT platform delivers proteins to the back of the eye.
•  Details on NT-501’s Phase II and III studies.
•  What 10 years of real-world data revealed about patients that use Notal Vision’s ForeseeHome.
•  How Notal Vision’s Home OCT is helping clinical trial investigators.
•  How Home OCT aids long-term treatment.
•  What sets InFocus Clinical apart from other CROs that run ophthalmology studies.
•  The latest additions to InFocus Clinical’s partnership program

[Listen Now]

Resources

OcuTerra Therapeutics           ocuterratx.com

NeuroTech                              neurotechpharmaceuticals.com

Notal Vision                            notalvision.com

InFocus Clinical                       infocusclinical.com

Carey Powers:                          ois.net/carey-powers

For more on at-home OCT, give Episode #377 with Anat Loewenstein, MD, a listen. 
https://ois.net/the-latest-on-at-home-oct-with-anat-loewenstein-md

At-home OCT enables daily monitoring of patients with neovasular age-related macular degeneration (AMD) and other patients that need a lot of follow-ups.

With host Carey Powers, Dr. Anat Loewenstein dives into at-home OCT innovation, application, and adoption.

Dr. Loewenstein is Head of the Department of Ophthalmology and Vice Dean at Tel Aviv Medical Center. She’s also a fellowship-trained vitreoretinal surgeon and has been heavily involved in research related to early AMD detection.

Why all the fuss about at-home OCT? An at-home monitoring solution will potentially lessen the number of appointments for patients who don’t need them. More-frequent monitoring could also help catch disease changes sooner so doctors can facilitate treatment asap.

Listen to the podcast today to discover:

• How at-home OCT works and the role artificial intelligence (AI) plays in image analysis.
• The patient experience when using at-home OCT.
• How disease activity alerts are delivered from the at-home device to the physician.
• Once a physician receives an alert, steps to take to get the patient into the clinic right away.
• The status of products closest to FDA approval, such as Notal Home OCT from Notal Vision.
• Dr. Loewenstein’s thoughts on the global health implications of at-home OCT.

[Listen Now]

Resources

Anat Loewenstein: linkedin.com/in/anat-loewenstein-b48a595

Carey Powers: ois.net/carey-powers